Browsing
     by title


0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

or enter first few letters:   
OK
Full Text
See detailLE PHARMACIEN HOSPITALIER : SITUATION EN 2008 ET PERSPECTIVES
Van Hees, Thierry ULg

Conference given outside the academic context (2008)

Detailed reference viewed: 25 (9 ULg)
Peer Reviewed
See detailPharmaco-economie des medicaments hypolipidemiants: analyse des facteurs influencant le rapport cout/efficacite.
Scheen, André ULg

in Revue Médicale de Liège (1998), 53(5), 270-5

The demonstration that stains reduce the risk of cardiovascular diseases, in both secondary and primary prevention trials, led to the recent publication of sophisticated pharmaco-economical studies. A lot ... [more ▼]

The demonstration that stains reduce the risk of cardiovascular diseases, in both secondary and primary prevention trials, led to the recent publication of sophisticated pharmaco-economical studies. A lot of factors may influence the cost-effectiveness ratio of the pharmacological intervention, especially the mode of calculation of various costs, the initial level of cardiovascular risk of the patients and the medico-economical particularities of each country. What so ever, available studies appear to justify the use of statins in secondary prevention, i.e. in coronary patients, even those with only a moderate hypercholesterolaemia, and, in primary prevention, i.e in hypercholesterolaemia individuals with obvious high risk of cardiovascular disease. [less ▲]

Detailed reference viewed: 39 (5 ULg)
Peer Reviewed
See detailPharmaco-economie du diabete de type 2.
Scheen, André ULg; Lefebvre, Pierre ULg

in Revue Médicale de Liège (1998), 53(5), 285-9

Type 2 diabetes has long been considered as a benign disease, whereas it is in fact associated with an enormous socio-economic cost. The major part of the burden of diabetes results from the management of ... [more ▼]

Type 2 diabetes has long been considered as a benign disease, whereas it is in fact associated with an enormous socio-economic cost. The major part of the burden of diabetes results from the management of complications (both direct and indirect costs), rather than from the various components of the antihyperglycaemic treatment itself. Solutions include a better prevention of the disease, an earlier diagnosis among individuals at risk, and an optimized management of diabetes, particularly in primary care settings, in order to avoid or retard the development of severe micro- or macroangiopathic complications which are particularly expensive. [less ▲]

Detailed reference viewed: 72 (1 ULg)
Peer Reviewed
See detailPharmacocinetique de l'insuline administree par voie sous-cutanee. Application au traitement par pompe portable (1).
Scheen, André ULg

in Diabète & Métabolisme (1989), 15(3), 128-38

Continuous subcutaneous insulin infusion is characterized by a basal insulin delivery rate to which insulin boluses are added. The basal delivery rate maintains a small insulin reserve in the local ... [more ▼]

Continuous subcutaneous insulin infusion is characterized by a basal insulin delivery rate to which insulin boluses are added. The basal delivery rate maintains a small insulin reserve in the local subcutaneous depot. This reserve averages 2 to 5 times the hourly basal rate at the steady-state which is reached after about 7 hours but depends on numerous factors: subcutaneous blood flow, skinfold thickness, insulin concentration, etc. It explains the pharmacokinetics time-lag of the system, more particularly the similar effects of a basal rate delivered in either a pulsatile/intermittent or a continuous manner, the lack of deleterious effect of a 1-h pump arrest, the 2-h delay before significant metabolic deterioration during a more prolonged interruption of the infusion, the delayed plasma insulin changes when the basal insulin delivery rate is doubled or reduced by half, etc. Insulin boluses pharmacokinetics is not fundamentally different from that of soluble insulin injection in conventional therapy. As an example, insulin boluses should ideally be given 30 min before the meals in order to better prevent post-prandial hyperglycaemia. However, the absence of intermediate zinc-insulin in the system may result in an earlier increase of plasma free insulin levels, which for instance allows a rapid correction of the metabolic alterations induced by a prolonged interruption of the basal infusion rate. This kinetics does not seem to be significantly altered by insulin concentration nor by the profile of the bolus but is affected by the insulin content of the subcutaneous depot at the time the bolus is delivered.(ABSTRACT TRUNCATED AT 250 WORDS) [less ▲]

Detailed reference viewed: 136 (0 ULg)
Full Text
Peer Reviewed
See detailPharmacodynamics of follicle stimulating hormone (FSH) in postmenopausal women during pulsed estrogen therapy: Evidence that FSH release and synthesis are controlled by distinct pathways
Christin-Maitre, S.; Laveille, C.; Collette, Julien ULg et al

in Journal of Clinical Endocrinology and Metabolism (2003), 88(11), 5405-5413

17beta-Estradiol (E2) exerts negative feedback effects at the hypothalamo-pituitary level on serum FSH. This study investigated the effects of repeated daily administration of intranasal E2 (S21400) on ... [more ▼]

17beta-Estradiol (E2) exerts negative feedback effects at the hypothalamo-pituitary level on serum FSH. This study investigated the effects of repeated daily administration of intranasal E2 (S21400) on the pharmacokinetics (PK) of E2 and estrone (E1) and the pharmacodynamics (PD) of FSH and assessed the PK/PD relationship between E2 and FSH using population model-dependent analysis. Postmenopausal volunteers (n = 24) received according to a balanced cross-over design, two 28-d treatments separated by a 2-month wash-out period: 300 mug E2, either alone or combined with oral dydrogesterone (20 mg/d) during the last 14 d of one of the treatments. Absorption of E2 was rapid, with maximal plasma concentrations at 10-30 min, returning to postmenopausal levels within 12 h. Over the 24-h period, FSH levels showed a U curve, with a minimum around 8 h after E2 administration. Moreover, over the treatment period, FSH basal values decreased by 17% between d 1 and 14 and an additional 5% between d 14 and 28. A PK/PD model described these short- and mid-term effects, possibly reflecting separate regulation mechanisms by E2 on FSH release and biosynthesis, respectively. The administration of progestin had no influence on E1, E2, and FSH model parameters. This study suggests that daily transient tissue exposure to E2 after pulsed estrogen therapy elicits short- and mid-term effects on the gonadotropin axis. [less ▲]

Detailed reference viewed: 12 (2 ULg)
See detailPharmacodynamie
Lekeux, Pierre ULg

in Delannoy, I. (Ed.) Le Grand Livre des AINS (1991)

Detailed reference viewed: 9 (0 ULg)
Peer Reviewed
See detailPharmacodynamie des aminoglycosides et optimisation de leur pharmacocinétque en néonatologie
Battisti, Oreste ULg; Langhendries, J. P.; Bertrand, J. M. et al

Conference (1997)

Detailed reference viewed: 18 (1 ULg)
Full Text
Peer Reviewed
See detailPharmacogenetics of infliximab in Crohn's disease
Dideberg, Vinciane ULg; Louis, Edouard ULg; Bours, Vincent ULg

in Acta Endoscopica (2007), 37(4), 521-530

Pharmacogenetic studies will certainly contribute to a better management of medication in inflammatory bowel diseases. Infliximab is the most efficient drug in refractory and fistulising Crohn's disease ... [more ▼]

Pharmacogenetic studies will certainly contribute to a better management of medication in inflammatory bowel diseases. Infliximab is the most efficient drug in refractory and fistulising Crohn's disease. However, about one third of the patients do not respond to this treatment. Several studies have been performed to identify predictive factors of the response to infliximab in CD. We attempt to summarize the current knowledge on the use of infliximab in CD and focus on the result of these studies and more particularly on pharmacogenetic aspects. [less ▲]

Detailed reference viewed: 55 (3 ULg)
See detailPharmacognosie - Volume 2
Angenot, Luc ULg; Tits, Monique ULg; Frederich, Michel ULg

Learning material (2010)

Le volume 2 est consacré aux grands classiques de la pharmacognosie dont ont été isolés de très nombreux principes actifs (souvent des alcaloïdes) qui ont marqué l'histoire de la pharmacie et de la ... [more ▼]

Le volume 2 est consacré aux grands classiques de la pharmacognosie dont ont été isolés de très nombreux principes actifs (souvent des alcaloïdes) qui ont marqué l'histoire de la pharmacie et de la pharmacologie.Les chapitres suivants seront abordés: analgésiques (pavot,opium, colchique...); Solanacées à activité parasympatholytiques ( belladone, stramoine, jusquiames...); dérivés de l'ergot de seigle; médicaments des troubles cérébraux de la sénescence ( ginkgo, amaryllidacées à galanthamine...); drogues alcaloïdiques psychoactives ( coca, éphédra, khat, psilocybes, peyotl, harmel, yagé, iboga...); hallucinogènes non alcaloïdiques ( cannabis, sauge des devins..); poisons agissant sur la neurotransmission :cholinergiques ( jaborandi, éséré...), paralysants neuro-musculaires (curares) et antagonistes de la glycine ( noix-vomique); antiparasitaires (malaria et amibiase): quinquinas, armoises, ipécas; anticancéreux : lignanes ( Podophyllum), diterpènes des ifs (Taxus sp), alcaloïdes indoliques ( Catharanthus roseus, Camptotheca ...), divers ( origine marine, épices...); plantes toxiques de l'environnement ( toxicité par contact ou par ingestion) [less ▲]

Detailed reference viewed: 124 (17 ULg)
See detailPharmacognosie Volume 1
Angenot, Luc ULg; Tits, Monique ULg

Learning material (2009)

Le volume 1 est principalement consacré à la phytochimie. Le cours est subdivisé suivant les différentes classes chimiques des métabolites primaires et secondaires impliqués soit dans l'activité des ... [more ▼]

Le volume 1 est principalement consacré à la phytochimie. Le cours est subdivisé suivant les différentes classes chimiques des métabolites primaires et secondaires impliqués soit dans l'activité des plantes soit dans leur toxicité ou encore présentant des applications en pharmacotechnie ou dans l'alimentation. La connaissance des structures ( basée sur leur origine biosynthétique) est très importante pour évaluer leur solubilité, leur stabilité et ainsi mieux comprendre les processus d'extraction et les méthodes spécifiques de contrôle ( plantes entières ou pulvérisées, , extraits, huiles essentielles, huiles grasses, exsudats...). dans de nombreux cas, une relation structure-activité pharmacologique ou physiologique est établie. [less ▲]

Detailed reference viewed: 75 (11 ULg)
See detailPharmacognosie Volume 3
Angenot, Luc ULg; Tits, Monique ULg; Frederich, Michel ULg

Learning material (2010)

Le volume 3 est principalement consacré à la phytothérapie (intérêt et limites) avec des notions concernant aussi bien la médecine traditionnelle que les développements les plus récents ( y compris pour ... [more ▼]

Le volume 3 est principalement consacré à la phytothérapie (intérêt et limites) avec des notions concernant aussi bien la médecine traditionnelle que les développements les plus récents ( y compris pour certains s'appuyant sur des études cliniques) en matière de phytomédicaments. La classification se fait suivant les activités pharmacologiques de ces plantes. Au terme de ce cours, les étudiants doivent pouvoir faire la distinction entre les différentes formes pharmaceutiques à base de produits d'origine naturelle ( poudres, extraits sec et autres), les concentrations en principes actifs et traceurs y étant bien différentes. Les différences entre les médicaments enregistrés et les compléments alimentaires sont également bien mises en évidence car les exigences relatives au contrôle de qualité et à la stabilité des produits finis sont très différentes. A ce sujet l'annexe du volume 3 est consacrée au contrôle de qualité des plantes en insistant sur les méthodes et monographies de la pharmacopée européenne qui joue un rôle essentiel dans ce domaine. [less ▲]

Detailed reference viewed: 95 (11 ULg)
See detailPharmacognosie volume I
Frederich, Michel ULg; Tits, Monique ULg; Angenot, Luc ULg

Learning material (2010)

Detailed reference viewed: 42 (19 ULg)
See detailPharmacognosie volume II
Frederich, Michel ULg; Tits, Monique ULg; Angenot, Luc ULg

Learning material (2011)

Detailed reference viewed: 25 (2 ULg)
See detailPharmacognosie volume III
Frederich, Michel ULg; Tits, Monique ULg; Angenot, Luc ULg

Learning material (2011)

Detailed reference viewed: 48 (6 ULg)
Full Text
Peer Reviewed
See detailPharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin.
Scheen, André ULg

in Expert Opinion on Drug Metabolism & Toxicology (2010), 6(10), 1265-76

IMPORTANCE OF THE FIELD: Type 2 diabetes is an increasingly prevalent disease resulting from various complex combinations of defects in insulin secretion and insulin action. Adequate blood glucose control ... [more ▼]

IMPORTANCE OF THE FIELD: Type 2 diabetes is an increasingly prevalent disease resulting from various complex combinations of defects in insulin secretion and insulin action. Adequate blood glucose control is necessary to minimize complications. DPP IV inhibitors (sitagliptin, vildagliptin, saxagliptin) offer new options for combined pharmacological therapy. AREAS COVERED IN THIS REVIEW: An extensive literature search was performed to analyze the potential pharmacokinetic (PK) and pharmacodynamic (PD) interactions between metformin (first-line drug for the management of type 2 diabetes) and sitagliptin (first commercialized DPP IV inhibitor). Metformin and sitagliptin may be administered together, either separately or in fixed-dose combination. WHAT THE READER WILL GAIN: Updated information about PK/PD data on metformin alone, sitagliptin alone and sitagliptin plus metformin. Metformin and sitagliptin are not prone to PK drug-drug interactions. Their co-administration, either separately or in a fixed-dose combination, improves blood glucose control more potently than either compound separately, without hypoglycemia and without increasing metformin-related gastrointestinal side effects. TAKE HOME MESSAGE: The combination sitagliptin plus metformin may be used as a first- or second-line therapy in the management of type 2 diabetes. [less ▲]

Detailed reference viewed: 58 (2 ULg)
Peer Reviewed
See detailPharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor.
Scheen, André ULg

in Clinical pharmacokinetics (2014), 53(3), 213-25

Empagliflozin is an orally active, potent and selective inhibitor of sodium glucose co-transporter 2 (SGLT2), currently in clinical development to improve glycaemic control in adults with type 2 diabetes ... [more ▼]

Empagliflozin is an orally active, potent and selective inhibitor of sodium glucose co-transporter 2 (SGLT2), currently in clinical development to improve glycaemic control in adults with type 2 diabetes mellitus (T2DM). SGLT2 inhibitors, including empagliflozin, are the first pharmacological class of antidiabetes agents to target the kidney in order to remove excess glucose from the body and, thus, offer new options for T2DM management. SGLT2 inhibitors exert their effects independently of insulin. Following single and multiple oral doses (0.5-800 mg), empagliflozin was rapidly absorbed and reached peak plasma concentrations after approximately 1.33-3.0 h, before showing a biphasic decline. The mean terminal half-life ranged from 5.6 to 13.1 h in single rising-dose studies, and from 10.3 to 18.8 h in multiple-dose studies. Following multiple oral doses, increases in exposure were dose-proportional and trough concentrations remained constant after day 6, indicating a steady state had been reached. Oral clearance at steady state was similar to corresponding single-dose values, suggesting linear pharmacokinetics with respect to time. No clinically relevant alterations in pharmacokinetics were observed in mild to severe hepatic impairment, or in mild to severe renal impairment and end-stage renal disease. Clinical studies did not reveal any relevant drug-drug interactions with several other drugs commonly prescribed to patients with T2DM, including warfarin. Urinary glucose excretion (UGE) rates were higher with empagliflozin versus placebo and increased with dose, but no relevant impact on 24-h urine volume was observed. Increased UGE resulted in proportional reductions in fasting plasma glucose and mean daily glucose concentrations. [less ▲]

Detailed reference viewed: 13 (1 ULg)
Full Text
Peer Reviewed
See detailPharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease.
Scheen, André ULg

in Expert opinion on drug metabolism & toxicology (2014)

Introduction: Patients with type 2 diabetes have an increased risk of chronic liver disease (CLD) such as non-alcoholic fatty liver disease and steatohepatitis and about one-third of cirrhotic patients ... [more ▼]

Introduction: Patients with type 2 diabetes have an increased risk of chronic liver disease (CLD) such as non-alcoholic fatty liver disease and steatohepatitis and about one-third of cirrhotic patients have diabetes. However, the use of several antidiabetic agents may be a cause for concern in the case of hepatic impairment (HI). Areas covered: An extensive literature search was performed to analyze the influence of HI on the pharmacokinetics (PK) of glucose-lowering agents and the potential consequences for clinical practice as far as the efficacy/safety balance of their use in diabetic patients with CLD is concerned. Expert opinion: Almost no PK studies have been published regarding metformin, sulfonylureas, thiazolidinediones and alpha-glucosidase inhibitors in patients with HI. Only mild changes in PK of glinides, dipeptidyl peptidase-4 inhibitors and sodium glucose cotransporters type 2 inhibitors were observed in dedicated PK studies in patients with various degrees of HI, presumably without major clinical relevance although large clinical experience is lacking. Glucagon-like peptide-1 receptor agonists have a renal excretion rather than liver metabolism. Rare anecdotal case reports of hepatotoxicity have been described with various glucose-lowering agents contrasting with numerous reassuring data. Nevertheless, caution should be recommended, especially in patients with advanced cirrhosis, including with the use of metformin. [less ▲]

Detailed reference viewed: 4 (0 ULg)
Full Text
Peer Reviewed
See detailPharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease.
SCHEEN, André ULg

in Expert Opinion on Drug Metabolism & Toxicology (2013)

Introduction: People with chronic kidney disease (CKD) of stages 3 - 5 (creatinine clearance < 60 ml/min) represent approximately 25% of patients with type 2 diabetes mellitus (T2DM), but the problem is ... [more ▼]

Introduction: People with chronic kidney disease (CKD) of stages 3 - 5 (creatinine clearance < 60 ml/min) represent approximately 25% of patients with type 2 diabetes mellitus (T2DM), but the problem is underrecognized or neglected in clinical practice. However, most oral antidiabetic agents have limitations in case of renal impairment (RI), either because they require a dose adjustment or because they are contraindicated for safety reasons. Areas covered: The author performed an extensive literature search to analyze the influence of RI on the pharmacokinetics (PK) of glucose-lowering agents and the potential consequences for clinical practice. Expert opinion: As a result of PK interferences and for safety reasons, the daily dose should be reduced according to glomerular filtration rate (GFR) or even the drug is contraindicated in presence of severe CKD. This is the case for metformin (risk of lactic acidosis) and for many sulfonylureas (risk of hypoglycemia). At present, however, the exact GFR cutoff for metformin use is controversial. New antidiabetic agents are better tolerated in case of CKD, although clinical experience remains quite limited for most of them. The dose of DPP-4 inhibitors should be reduced (except for linagliptin), whereas both the efficacy and safety of SGLT2 inhibitors are questionable in presence of CKD. [less ▲]

Detailed reference viewed: 28 (3 ULg)
Peer Reviewed
See detailPharmacokinetic evaluation of a long-acting sulfamethazine bolus for lambs
Evrard, Brigitte ULg; Delahaut, Philippe; Delattre, Luc ULg

in Proceedings of 21th International Symposium on controlled release of Bioactive Materials (1994)

Detailed reference viewed: 6 (0 ULg)